Chardan Capital Issues Optimistic Forecast for ABUS Earnings

Arbutus Biopharma Co. (NASDAQ:ABUS) – Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for Arbutus Biopharma in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings per share of ($0.30) for the year, up from their previous forecast of ($0.38). Chardan Capital has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

Several other research firms also recently weighed in on ABUS. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. StockNews.com downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, Arbutus Biopharma currently has an average rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Stock Performance

NASDAQ:ABUS opened at $3.50 on Thursday. The stock has a market cap of $663.22 million, a price-to-earnings ratio of -8.14 and a beta of 1.93. Arbutus Biopharma has a one year low of $2.30 and a one year high of $4.73. The business’s 50-day simple moving average is $3.34 and its 200 day simple moving average is $3.57.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The firm had revenue of $1.57 million for the quarter, compared to analyst estimates of $2.20 million.

Hedge Funds Weigh In On Arbutus Biopharma

Several institutional investors have recently modified their holdings of the company. Whitefort Capital Management LP boosted its stake in Arbutus Biopharma by 2.9% during the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock valued at $43,301,000 after purchasing an additional 373,949 shares during the period. Vanguard Group Inc. boosted its position in Arbutus Biopharma by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company’s stock worth $29,367,000 after acquiring an additional 62,282 shares during the period. Two Seas Capital LP grew its stake in shares of Arbutus Biopharma by 4.2% in the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock worth $28,583,000 after purchasing an additional 353,568 shares in the last quarter. State Street Corp lifted its holdings in Arbutus Biopharma by 50.2% in the third quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock worth $16,967,000 after purchasing an additional 1,472,652 shares during the period. Finally, Geode Capital Management LLC grew its position in Arbutus Biopharma by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company’s stock valued at $11,390,000 after buying an additional 33,536 shares in the last quarter. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.